JP2022527412A5 - - Google Patents
Info
- Publication number
- JP2022527412A5 JP2022527412A5 JP2021560649A JP2021560649A JP2022527412A5 JP 2022527412 A5 JP2022527412 A5 JP 2022527412A5 JP 2021560649 A JP2021560649 A JP 2021560649A JP 2021560649 A JP2021560649 A JP 2021560649A JP 2022527412 A5 JP2022527412 A5 JP 2022527412A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- cancer
- inhibitor
- composition according
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832509P | 2019-04-11 | 2019-04-11 | |
| US62/832,509 | 2019-04-11 | ||
| PCT/US2020/027784 WO2020210711A1 (en) | 2019-04-11 | 2020-04-10 | Compositions and methods of using seneca valley virus (svv) for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527412A JP2022527412A (ja) | 2022-06-01 |
| JP2022527412A5 true JP2022527412A5 (https=) | 2023-04-18 |
Family
ID=72752125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560649A Pending JP2022527412A (ja) | 2019-04-11 | 2020-04-10 | がんの治療にセネカバレーウイルス（ｓｖｖ）を使用する組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220202884A1 (https=) |
| EP (1) | EP3952896A4 (https=) |
| JP (1) | JP2022527412A (https=) |
| KR (1) | KR20220006531A (https=) |
| CN (1) | CN113924106A (https=) |
| AU (1) | AU2020272054A1 (https=) |
| BR (1) | BR112021020369A2 (https=) |
| CA (1) | CA3136671A1 (https=) |
| IL (1) | IL287117A (https=) |
| WO (1) | WO2020210711A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096201A1 (en) | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| CN109679927B (zh) * | 2019-02-25 | 2021-04-09 | 中国农业科学院兰州兽医研究所 | 猪塞内加谷病毒、猪塞内加谷病毒灭活疫苗的制备方法、猪塞内加谷病毒灭活疫苗和应用 |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CA3207860A1 (en) * | 2021-01-11 | 2022-07-14 | Seneca Therapeutics, Inc. | Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor |
| WO2023107878A1 (en) * | 2021-12-06 | 2023-06-15 | Oncorus, Inc. | Compositions and methods of seneca valley virus (svv) related cancer therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201217892D0 (en) * | 2012-10-05 | 2012-11-21 | Virttu Biolog Ltd | Treatment of cancer |
| WO2017096201A1 (en) * | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
-
2020
- 2020-04-10 WO PCT/US2020/027784 patent/WO2020210711A1/en not_active Ceased
- 2020-04-10 KR KR1020217036719A patent/KR20220006531A/ko not_active Ceased
- 2020-04-10 AU AU2020272054A patent/AU2020272054A1/en active Pending
- 2020-04-10 JP JP2021560649A patent/JP2022527412A/ja active Pending
- 2020-04-10 EP EP20787585.7A patent/EP3952896A4/en active Pending
- 2020-04-10 CA CA3136671A patent/CA3136671A1/en active Pending
- 2020-04-10 BR BR112021020369A patent/BR112021020369A2/pt unknown
- 2020-04-10 CN CN202080040517.7A patent/CN113924106A/zh active Pending
- 2020-04-10 US US17/601,768 patent/US20220202884A1/en active Pending
-
2021
- 2021-10-10 IL IL287117A patent/IL287117A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527412A5 (https=) | ||
| Su et al. | The role of Epstein–Barr virus in nasopharyngeal carcinoma | |
| Yu et al. | Clinical trials with oncolytic adenovirus in China | |
| Bommareddy et al. | Integrating oncolytic viruses in combination cancer immunotherapy | |
| Chan et al. | Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors | |
| Adamson et al. | Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies | |
| Jilg et al. | Kinetic differences in the induction of interferon stimulated genes by interferon‐α and interleukin 28B are altered by infection with hepatitis C virus | |
| Feng et al. | Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas | |
| Padovan et al. | Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection | |
| JP7409612B2 (ja) | トリパタイトモチーフ含有蛋白質１６（ｔｒｉｍ１６）シグナル伝達を誘導するための組成物及び方法 | |
| Li et al. | MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells | |
| Tafvizi et al. | Detection of human cytomegalovirus in patients with colorectal cancer by nested-PCR | |
| Bockmann et al. | Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus–infected hepatocytes | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| Salavatiha et al. | The role of endogenous retroviruses‐K in human cancer | |
| JP2022541234A5 (https=) | ||
| Chen et al. | The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials | |
| Yang et al. | VPS9D1-AS1 overexpression amplifies intratumoral TGF-β signaling and promotes tumor cell escape from CD8+ T cell killing in colorectal cancer | |
| Daei Sorkhabi et al. | The basis and advances in clinical application of cytomegalovirus-specific cytotoxic T cell immunotherapy for glioblastoma multiforme | |
| Yuan et al. | Epstein–Barr virus-mediated immune evasion in tumor promotion | |
| JP2022536412A5 (https=) | ||
| Choi et al. | DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma | |
| Zhang et al. | IFIT3 inhibits Epstein‐Barr virus reactivation via upregulating innate immunity | |
| Munyon et al. | Induction of cytoplasmic ribonucleic acid (RNA) synthesis in vaccinia-infected LM cells during inhibition of protein synthesis | |
| Malik et al. | The role of type III interferons in human disease |